Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes

Hematology
Ramzi JeddiBalkis Meddeb

Abstract

Severe sepsis defined as infection-induced organ dysfunction or hypoperfusion abnormalities predispose to septic shock and increased mortality in neutropenic setting. We aimed at determining predictors of severe sepsis in neutropenic patients. Between 1 October and 31 December 2007, 41 patients (21 with acute myeloid leukemia, 19 with acute lymphoid leukemia and one with autologous stem cell transplantation for a mantle cell lymphoma) with chemotherapy-induced neutropenia (<0.5 x 10(9)/l) lasting for more than 7 days were included in this study. The median age was 28 years (range: 3-58 years). All patients were on oral antibacterial (colistin and gentamicin) and anti-fungal (amphotericin B) prophylaxis. The first neutropenic febrile episode was treated with piperacillin/tazobactam and colistin IV; if the patient remains febrile at 48 h from the start of this first line of treatment, amphotericin B i.v. is added. Imipenem was introduced in the case of non-response and finally glycopeptides were introduced according to the IDSA criteria. Severe sepsis and septic shock are defined according to the criteria of the consensus conference of the ACCP/SCCM excluding the leukocyte count since all the patients were neutropenic. Ninety-fou...Continue Reading

References

Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W T HughesL S Young
May 1, 1970·The American Journal of Physiology·A M Lefer, J Martin
Jan 1, 1997·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·F Baxter
Jul 16, 1997·JAMA : the Journal of the American Medical Association·K E SandsUNKNOWN Academic Medical Center Consortium Sepsis Project Working Group
May 18, 1999·European Heart Journal·S PriceT W Evans
Feb 24, 2001·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G Maschmeyer, I Braveny
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E SantolayaM Zubieta
Jan 17, 2002·The New England Journal of Medicine·E RiversUNKNOWN Early Goal-Directed Therapy Collaborative Group
Feb 19, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Walter T HughesLowell S Young
Apr 19, 2002·Journal of Applied Physiology·Michael P Margarson, Neil C Soni
Apr 18, 2003·The New England Journal of Medicine·Greg S MartinMarc Moss
Jul 14, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean Klastersky
Nov 9, 2004·American Journal of Respiratory and Critical Care Medicine·Corinne AlbertiUNKNOWN European Sepsis Study Group
Oct 26, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Emanuel P RiversKandis K Rivers
Apr 22, 2006·American Journal of Physical Medicine & Rehabilitation·Nancy L DudekShawn C Marshall
Oct 20, 2006·The New England Journal of Medicine·James A Russell
Jun 15, 2007·Journal of the American Society of Nephrology : JASN·Steven M Brunelli, Stanley Goldfarb
Aug 19, 2007·Circulation·M W Merx, C Weber
Sep 14, 2007·Hematology·Jeddi RamziMeddeb Balkis
Dec 26, 2007·Critical Care Medicine·R Phillip DellingerUNKNOWN World Federation of Societies of Intensive and Critical Care Medicine

❮ Previous
Next ❯

Citations

Feb 22, 2012·Current Opinion in Pulmonary Medicine·Jean-Philippe LanoixYoucef Douadi
Mar 31, 2012·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Juan C Jaramillo-BustamanteJosé Bareño-Silva
Mar 24, 2016·Virulence·Giulia Gustinetti, Malgorzata Mikulska
Jun 28, 2015·Acta Oto-laryngologica·Takahiro SasakiHidenori Inohara
May 20, 2016·Future Microbiology·Paola Tatarelli, Malgorzata Mikulska
Oct 6, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Müge GünalpAtilla Halil Elhan
Jun 22, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Judith A E M ZechaLudi E Smeele
May 6, 2015·Current Infectious Disease Reports·Andre C Kalil, Steven M Opal
Jul 22, 2020·The Journal of Infectious Diseases·Randy J McCreeryAndre C Kalil
Apr 12, 2019·Frontiers in Physiology·Cristiane Assunção da Costa Cunha MafraAurigena Antunes de Araújo
Jul 3, 2021·Medicina·Giuseppe BertozziRaffaele La Russa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.